Sustanon 300 mg/ml - Royal Pharmaceuticals
Sustanon 300 van Royal Pharmaceuticals is een testosteron onderzoekspreparaat met gemengde esters dat testosteronpropionaat (50 mg), fenylpropionaat (70 mg), isocaproaat (70 mg) en decanoaat (110 mg) per ml bevat (totaal 300 mg/ml). Deze combinatie levert zowel een snelle als langdurige afgifte van testosteron, waardoor het een standaardreferentie is voor onderzoek naar androgeensignalering, farmacokinetiek, erytropoëse en endocriene regulatie. Alleen voor laboratoriumonderzoek - niet voor menselijk of diergeneeskundig gebruik.
€ 49.00
Beschrijving
Sustanon 300 mg/ml – Royal Pharmaceuticals (Mixed-Ester Testosterone)
Category: Injectable Mixed-Ester Testosterone (Research Only)
Brand: Koninklijke Farmaceutische Producten
Strength: 300 mg/ml total testosterone
Ester Breakdown: T. Propionate 50 mg, T. Phenylpropionate 70 mg, T. Isocaproate 70 mg, T. Decanoate 110 mg
Packing: 10 × 1 ml ampoules
Origin: United Kingdom
Price: €49
Use Notice: For laboratory and analytical research only — not for therapeutic, performance-enhancing or veterinary use.
🧪 What Is Sustanon 300?
Sustanon 300 is a mixed-ester testosterone formulation combining fast, medium, and long-acting esters in a single intramuscular injection.
This composition creates:
- A rapid onset from short-ester testosterone propionate
- Sustained release from intermediate esters (phenylpropionate, isocaproate)
- Long-term maintenance via testosterone decanoate
Mixed-ester testosterone solutions are widely referenced in medical, pharmacological and endocrine research, particularly in the context of male hypogonadism, androgen replacement therapy and anabolic-androgenic signalling.
🔬 Key Technical Characteristics
- Pharmacological class: Anabolic-androgenic steroid (androgen receptor agonist)
- Route: Intramuscular (I.M.) only
- Release pattern: Rapid–intermediate–prolonged due to ester diversity
- Approximate effective duration: ~2–3 weeks per injection (literature-based)
- WADA status: Exogenous testosterone and all esters are prohibited at all times (S1 – Anabolic Agents)
🧬 Mechanism of Action
After injection, esterases gradually hydrolyse each testosterone ester, releasing free testosterone into circulation. Free testosterone:
- Binds to androgen receptors in muscle, bone and reproductive tissues
- Modulates transcription of androgen-responsive genes
- Increases protein synthesis and nitrogen retention
- Supports erythropoiesis and increases hemoglobin/hematocrit
- Aromatises to estradiol and reduces to DHT, influencing multiple hormonal pathways
📚 Research & Clinical Context
- Mild–severe hypogonadism: Testosterone esters restore libido, mood, bone density and body composition.
- Pharmacokinetic research: Mixed-ester profiles provide comparative data for absorption and release rates.
- Endocrine studies: Used to evaluate HPG-axis suppression and recovery mechanisms.
- Metabolic studies: Testosterone affects insulin sensitivity, lipid profiles and muscle–fat partitioning.
Note: These refer to medical literature and do not imply suitability for non-medical use.
📈 Potential Research-Level Observations
- Increase in lean body mass and nitrogen retention
- Improved bone mineral density in hypogonadal models
- Enhanced red-blood-cell production
- Alterations in lipid profile and glucose regulation
- Clear suppression of endogenous LH/FSH signalling
⚠️ Possible Adverse Effects (Research Context)
Endocrine & Reproductive
- Suppression of LH/FSH
- Reduced endogenous testosterone
- Decreased spermatogenesis; potential infertility
Cardiovascular & Haematological
- Elevated hematocrit / polycythaemia
- Lower HDL, increased LDL
- Potential blood-pressure changes
Androgenic Effects
- Acne, oily skin, hair loss
- Possible virilisation effects in female exposure
Hepatic & Metabolic
- Injectable esters have low intrinsic hepatotoxicity but may influence metabolic enzymes
Other
- Mood variation, irritability, aggression
- Injection-site irritation or pain
🛑 Compliance & Regulatory Notice
- Prescription-only in most jurisdictions
- Testosterone (all forms) is a prohibited WADA S1 anabolic agent
- Handling requires adherence to local laws and research regulations
📊 Technical Data Table
| Parameter | Value |
|---|---|
| Product name | Sustanon 300 mg/ml - Royal Pharmaceuticals |
| Active substance | Mixed testosterone esters |
| Composition | 50 mg Propionate; 70 mg Phenylpropionate; 70 mg Isocaproate; 110 mg Decanoate |
| Concentration | 300 mg/ml |
| Formulation | Sterile oil solution for I.M. use |
| Packing | 10 × 1 ml ampoules |
| Primary class | Anabolic-androgenic steroid (AAS) |
| WADA status | Prohibited (S1 – anabolic agents) |
For laboratory and research use only — not for human or veterinary administration.
There are no reviews yet.
